AbbVie (prior sponsor, Abbott)
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, AbbVie (prior sponsor, Abbott) sits in the top decile of US sponsors by registered trial count (#265 of 15,742 sponsors by registered trial count).
AbbVie (prior sponsor, Abbott): 88 sponsored US clinical trials, none currently recruiting.
AbbVie (prior sponsor, Abbott) sponsors 88 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 83 completed. 17 of these trials are in Phase 3-4 (later-stage) and 70 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lupron, with 1 trials.
Top-decile sponsor footprint
AbbVie (prior sponsor, Abbott) ranks in the top decile of sponsors by registered trial count (#265 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
83 of 88 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
88 total, page 2 of 2
A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
NCT00920764
Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects
NCT00360568
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
NCT00872196
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
NCT00851890
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
NCT00357994
Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
NCT00667446
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
NCT00707889
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
NCT00763321
Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)
NCT00761150
A Follow-up Assessment of Resistance to ABT-333 in Hepatitis C Virus (HCV)-Infected Subjects Who Have Received ABT-333 in ABT-333 Studies
NCT00726882
Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer
NCT00645177
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00710580
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT00716534
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00691964
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00686933
A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases
NCT00649207
Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00640185
Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00640419
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
NCT00616772
The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4
NCT00497146
Open Label Continuation Study in Moderate to Severe Psoriasis
NCT00626002
Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
NCT00335153
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00570986
A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
NCT00548925
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
NCT00517920
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
NCT00528697
Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
NCT00507936
Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00517790
Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)
NCT00635193
Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib
NCT00486538
A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies
NCT00445198
A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)
NCT00443391
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies
NCT00406809
A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer
NCT00297089
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00292396
A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer
NCT00401570
Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
NCT00086671
Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis
NCT00195663
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 51 |
| Phase 3 | 16 |
| Phase 4 | 1 |
How the AbbVie (prior sponsor, Abbott) early-phase archive is shaped
88 indexed studies, none listed as recruiting (0% open); 83 completed (94%).
Phase mix: 17 late (III/IV) vs 70 early (I/II) (early-phase heavy).
Top condition: Lupron (1 trial), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
AbbVie (prior sponsor, Abbott): archived-pipeline peers nationwide
Peers matched on 88 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
AbbVie (prior sponsor, Abbott) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 88 archived trials
- Pacira Pharmaceuticals · 88 trials · 6% recruiting
- University of Medicine and Dentistry of New Jersey · 88 trials · 0% recruiting
- Abbott Nutrition · 89 trials · 1% recruiting
- Florida International University · 89 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this AbbVie (prior sponsor, Abbott) page
88 registered trials is a research-attention snapshot, not an endorsement of AbbVie (prior sponsor, Abbott) or any single study.
- None of AbbVie (prior sponsor, Abbott)'s trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Lupron is the condition AbbVie (prior sponsor, Abbott) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lupron trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. AbbVie (prior sponsor, Abbott) pipeline card: 88 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.